Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.

ANI Pharmaceuticals and Eton Pharmaceuticals have announced the launch of their Carbaglu rival, with the companies having been granted a Competitive Generic Therapy designation by the FDA, along with 180 days of related exclusivity. ANI has also announced receiving FDA approval for its abbreviated new drug application for Mycobutin rival, Rifabutin capsules for 150mg dose. 

French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.

Eton Pharmaceuticals gets untitled letter for promotion of its Alkindi Sprinkle hydrocortisone granules for treatment of pediatric adrenal insufficiency. The agency sent two letters last year objecting to sponsored links after a decade pause.